[Federal Register Volume 59, Number 119 (Wednesday, June 22, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-15088]
[[Page Unknown]]
[Federal Register: June 22, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Revised Aggregate Production Quotas for Controlled Substances in
Schedules I and II
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final revised aggregate production quotas for 1994.
-----------------------------------------------------------------------
SUMMARY: This notice establishes revised 1994 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act (CSA).
EFFECTIVE DATE: This order is effective on June 22, 1994.
FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug &
Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for controlled substances in Schedules I and II each year. This
responsibility has been delegated to the Administrator of the DEA
pursuant to Sec. 0.100 of title 28 of the Code of Federal Regulations.
The Administrator, in turn, has redelegated this function to the Deputy
Administrator pursuant to 59 FR 23637 (May 6, 1994).
On April 13, 1994, a notice of the proposed revised 1994 aggregate
production quotas for certain controlled substances in Schedules I and
II was published in the Federal Register (59 FR 17568). All interested
parties were invited to comment on or object to these proposed
aggregate production quotas on or before May 13, 1994.
Several companies commented that the revised 1994 aggregate
production quotas for amphetamine, codeine (for sale), d-
desoxyephedrine, opium, oxycodone (for sale), pentobarbital and
secobarbital were insufficient to provide for the estimated medical,
scientific, research and industry needs of the United States, for
export requirements and for the establishment and maintenance of
reserve stocks.
The DEA has reviewed the involved companies' 1993 year-end
inventories, their initial 1994 manufacturing quotas, 1994 export
requirements and their actual and projected 1994 sales. Based on this
data, the DEA has adjusted the revised 1994 aggregate production quotas
for amphetamine, codeine (for sale), d-desoxyephedrine, opium,
oxycodone (for sale), pentobarbital and secobarbital to meet the
estimated medical, scientific, research and industrial needs of the
United States.
Regarding levorphanol, methylphenidate, phencyclidine and
sufentanil, DEA has received updated information from several
manufacturers which shows the necessity for adjustments of the revised
1994 aggregate production quotas for these controlled substances. The
adjustments will provide for the estimated medical, scientific,
research and industrial needs of the United States and for the
establishment and maintenance of reserve stocks. The DEA has adjusted
the 1994 revised aggregate production quotas for levorphanol,
methylphenidate, phencyclidine and sufentanil accordingly.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
Federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et. seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
Therefore, under the authority vested in the Attorney General by
section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator of the DEA by Sec. 0.100 of title 28 of
the Code of Federal Regulations, and redelegated to the Deputy
Administrator pursuant to 59 FR 23637 (May 6, 1994), the Deputy
Administrator hereby orders that the 1994 revised aggregate production
quotas, expressed in grams of anhydrous acid or base, be established as
follows:
------------------------------------------------------------------------
Established
Basic class revised 1994
quotas
------------------------------------------------------------------------
Schedule I:
2,5-Dimethoxyamphetamine.............................. 15,510,000
Schedule II:
Alfentanil............................................ 8,000
Amphetamine........................................... 787,000
Codeine (for sale).................................... 61,765,000
d-Desoxyephedrine..................................... 22,100
Diphenoxylate......................................... 638,000
Levorphanol........................................... 8,500
Methylphenidate....................................... 7,313,000
Opium................................................. 1,242,000
Oxycodone (for sale).................................. 3,853,000
Oxycodone (for conversion)............................ 5,400
Oxymorphone........................................... 2,420
Pentobarbital......................................... 17,000,000
Phencyclidine......................................... 62
Secobarbital.......................................... 550,000
Sufentanil............................................ 897
------------------------------------------------------------------------
Dated: June 15, 1994.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 94-15088 Filed 6-21-94; 8:45 am]
BILLING CODE 4410-09-M
